PRTA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PR

Mkt Cap

$429.4M

Volume

533.96K

Next Earnings

November 5th

Loading chart

PR

PRTAProthena Corporation plc Ordinary Shares

PRTA

Pay with—

Available Balance0.00

PR

Mkt Cap

$436.4M

Volume

533.96K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?In a comparison of two medical-biomedical stocks, CorMedix (CRMD) emerges as the superior value option over Prothena (PRTA). CRMD holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 13.48 and PEG ratio of 1.35. PRTA, ranked #3 (Hold) with a Value grade of F, has a forward P/E of 66.51 and PEG ratio of 1.99, indicating it is significantly more expensive relative to its growth prospects.Zacks Investment Research · Oct 8, 2026

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS InsiderThe transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.GlobeNewswire Inc. · Jul 7, 2026

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure BiomarkerNovo Nordisk presented Phase 2 trial results for Coramitug, an antibody targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug showed a statistically significant reduction in heart failure biomarker NT-proBNP and was well-tolerated.Benzinga · Nov 12, 2025

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's TherapyThe FDA now requires an additional MRI scan before the third Leqembi infusion to detect early signs of brain swelling (ARIA-E), a rare but potentially fatal side effect of the Alzheimer's treatment.Benzinga · Aug 29, 2025

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law FirmKuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Prothena Corporation PLC. Shareholders may be entitled to damages and corporate governance reforms.GlobeNewswire Inc. · Feb 17, 2025

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsightThe article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.GlobeNewswire Inc. · Feb 13, 2025

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical BenefitsProthena's Parkinson's drug prasinezumab, partnered with Roche, missed the primary endpoint in a Phase 2b study, but showed potential clinical benefits in secondary analyses.Benzinga · Dec 19, 2024

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsightThe rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as a key market driver.GlobeNewswire Inc. · Oct 14, 2024

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.Zacks Investment Research · Jun 24, 2024

Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.Zacks Investment Research · Jun 19, 2024

to start trading

PR

PRTAProthena Corporation plc Ordinary Shares

PRTA

Pay with—

Available Balance0.00

Your PositionYou don't own any PRTA yet.

Related Tickers

Earnings